Laboratory parameters from Clinical Benefit Response Criteria (CBR) and KSHV VL values among 11 participants with KICS treated with rituximab in combination with KS-directed therapies (liposomal doxorubicin or paclitaxel). All participants received a median of 3 months of prior KS-directed chemotherapy (range, 6-12 cycles of treatment) before rituximab. “Start” represents treatment initiation of rituximab and KS-directed chemotherapy, and “end” denotes laboratory values following rituximab and KS-directed treatment. Red dots represent participants who met the criteria for partial response as best response (supplemental Table 2) per the CBR. Wilcoxon signed rank tests highlight differences from baseline to the end of treatment in laboratory parameters among all participants who received rituximab-based therapy (see supplemental Table 3 for values).